TP53 and cancer: Inactivation of TP53 is expected to promote the aberrant cancer-like PASMC proliferation, responsible for medial hypertrophy and distal neomuscularization leading to pulmonary vasculature occlusion and increased pulmonary vascular resistance in these models of PH.